3200 Lakeside Dr.
Santa Clara
CA
95054
USA
(408) 845-3000
Related Content
March 15, 2013 — Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular ...
March 15, 2013
Feature | Dave Fornell
February 22, 2013 — Physicians have new tools for treating coronary chronic total occlusions (CTOs) after Abbott ...
February 22, 2013
Feature | Kamran Zamanian, Ph.D.
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents ...
February 04, 2013January 30, 2013 — January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData ...
January 30, 2013
January 29, 2013 — An estimated 17 million people throughout the world die annually of cardiovascular diseases ...
January 29, 2013
January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The ...
January 08, 2013
January 3, 2013 — Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food ...
January 03, 2013December 19, 2012 — Acute chest pain is one of the most common reasons people seek emergency care, and time is a ...
December 19, 2012
Feature | William Kent, M.D., MSc, Patrick McCarthy, M.D., Edwin McGee, M.D., Chris Malaisrie, M.D.
For chronic mitral valve regurgitation (MR) from degenerative disease, conventional open surgery provides a durable ...
December 17, 2012
November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are ...
November 02, 2012